India’s Cipla presses court to not honor Novartis Onbrez patent citing Lupin license deal

EJ Lane India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss ...

GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

Carly Helfand GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty ...

Novartis’ bid to widen Afinitor’s breast cancer reach falls short in PhIII

Carly Helfand Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod ...

Novartis psoriasis prospect tops J&J’s fast-growing Stelara in PhIII

Carly Helfand J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested ...

GSK shareholders to vote on Novartis megadeal in December

Carly Helfand Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline and Novartis worth more than $ 20 billion. FiercePharma News

FDA advisers spurn Novartis’ blood cancer drug, putting approval in doubt

Damian Garde Novartis' new multiple myeloma is treatment too risky to be approved, a group of FDA advisers voted, dealing a blow to the drugmaker and its hopes of launching the ...

J&J, Pfizer, Novartis are the in-demand pharmas among job-seekers, LinkedIn says

Tracy Staton Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it's always nice to know that would-be job seekers think ...

Novartis gears up for FDA scrutiny with a new blood cancer drug

Damian Garde Novartis believes its new oncology treatment can make a major difference for patients with multiple myeloma, a blood cancer with a particularly grim prognosis. But first ...

Like Novartis before it, AstraZeneca benefits big time from Ranbaxy issues

Eric Palmer Ranbaxy Laboratories in June finally managed to finesse its regulatory problems enough to get a generic of Novartis' Diovan to market, boosting its own fortunes while ...

Cipla petitions India to revoke Novartis respiratory drug patents, launches low-cost version of drug

Emily Wasserman Amid growing discontent from Big Pharma companies over India's patent-busting policies, generics maker Cipla is petitioning the country's government to revoke ...

Novartis sets sights on Philly amid a sweeping CAR-T collaboration

Damian Garde Novartis has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers ...

A tale of ‘two worlds’ for Novartis respiratory launches in U.S. and EU

Tracy Staton Targeting different markets naturally requires using different marketing strategies. But for Novartis, which is aiming to become a major respiratory player, its approaches ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS